Bortezomib
- Generic Name
- Bortezomib
- Brand Names
- Velcade, Bortezomib Accord, Bortezomib Hospira, Bortezomib Fresenius Kabi, Bortezomib Sun
- Drug Type
- Small Molecule
- Chemical Formula
- C19H25BN4O4
- CAS Number
- 179324-69-7
- Unique Ingredient Identifier
- 69G8BD63PP
- Background
Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells, is thought to be the main mechanism of action of bortezomib. However, multiple mechanisms may be involved in the anticancer activity of bortezomib.
Bortezomib was first synthesized in 1995. In May 2003, bortezomib became the first anticancer proteasome inhibitor that was approved by the FDA under the trade name VELCADE. Phase I, II, III, and IV clinical trials are undergoing to investigate the therapeutic efficacy of bortezomib in leukemia, myasthenia gravis, systemic lupus erythematosus, rheumatoid arthritis, and solid tumours.
- Indication
Bortezomib is indicated for the treatment of adults with multiple myeloma or mantle cell lymphoma.
- Associated Conditions
- Mantle Cell Lymphoma (MCL), Multiple Myeloma (MM)
- Associated Therapies
- -
HLA-Haploidentical Peripheral Blood Stem Cell Transplantation With Post-transplant Cyclophosphamide and Bortezomib
- First Posted Date
- 2019-02-21
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- Henry Ford Health System
- Target Recruit Count
- 15
- Registration Number
- NCT03850366
- Locations
- 🇺🇸
Henry Ford hospital, Detroit, Michigan, United States
Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease
- First Posted Date
- 2019-02-18
- Last Posted Date
- 2020-01-10
- Lead Sponsor
- Wei Zhao
- Target Recruit Count
- 1500
- Registration Number
- NCT03844360
- Locations
- 🇨🇳
State Key Laboratory of Experimental Haematology, Department of Paediatric Haematology, Institute of Haematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tanjin, Tianjin, China
An Open-label, Dose Escalation Study in Japanese Participants With Relapsed/Refractory Multiple Myeloma Who Have Failed Prior Anti Myeloma Treatments
- Conditions
- Interventions
- First Posted Date
- 2019-02-04
- Last Posted Date
- 2023-11-14
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 15
- Registration Number
- NCT03828292
- Locations
- 🇯🇵
GSK Investigational Site, Tokyo, Japan
Metformin, Nelfinavir, and Bortezomib in Treating Patients With Relapsed and/or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2019-02-04
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 9
- Registration Number
- NCT03829020
- Locations
- 🇺🇸
Mayo Clinic, Jacksonville, Florida, United States
🇺🇸Mayo Clinic in Rochester, Rochester, Minnesota, United States
Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2018-12-04
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT03763162
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
CURATE.AI Optimized Modulation for Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2018-11-29
- Last Posted Date
- 2023-09-06
- Lead Sponsor
- National University Hospital, Singapore
- Target Recruit Count
- 20
- Registration Number
- NCT03759093
- Locations
- 🇸🇬
National University Hospital, Singapore, Singapore
Treatment for Elderly Fit Newly Diagnosed Multiple Myeloma Patients Aged Between 65 and 80 Years
- Conditions
- Interventions
- First Posted Date
- 2018-11-15
- Last Posted Date
- 2022-09-14
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 462
- Registration Number
- NCT03742297
- Locations
- 🇪🇸
Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
🇪🇸Hospital Universitario de Cruces, Bilbao, Spain
🇪🇸Complejo Hospitalario Regional Reina Sofía, Córdoba, Spain
Comparison Between Bortezomib and Rituximab Plus Plasmapheresis in AMR
- First Posted Date
- 2018-11-09
- Last Posted Date
- 2023-07-18
- Lead Sponsor
- Shahid Beheshti University of Medical Sciences
- Target Recruit Count
- 20
- Registration Number
- NCT03737136
- Locations
- 🇮🇷
SBMU, Tehran, Iran, Islamic Republic of
Carfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma (COBRA)
- Conditions
- Interventions
- First Posted Date
- 2018-11-05
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 250
- Registration Number
- NCT03729804
- Locations
- 🇺🇸
University Of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois, United States
Daratumumab, Bortezomib, and Dexamethasone With or Without Venetoclax in Treating Patients With Relapsed or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2018-10-10
- Last Posted Date
- 2023-09-26
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT03701321
- Locations
- 🇺🇸
Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
🇺🇸Aurora Cancer Care-Milwaukee West, Wauwatosa, Wisconsin, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.